- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Eagan Today
By the People, for the People
Predictive Oncology and Carlsmed Head to Head Comparison
Two small-cap manufacturing companies in the healthcare industry, but which one is the superior business?
Mar. 27, 2026 at 9:58am
Got story updates? Submit your updates here. ›
Carlsmed (NASDAQ:CARL) and Predictive Oncology (NASDAQ:AGPU) are both small-cap manufacturing companies operating in the healthcare industry. This article provides a head-to-head comparison of the two companies based on factors like analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends, and risk.
Why it matters
This comparison is relevant for investors looking to understand the relative strengths and weaknesses of these two healthcare technology companies and determine which one may be the better investment option.
The details
The analysis finds that Carlsmed has stronger consensus ratings from analysts and higher potential upside, suggesting it is viewed more favorably. Carlsmed also has better financial metrics like net margins, return on equity, and return on assets compared to Predictive Oncology. While Predictive Oncology has lower revenue, it has higher earnings per share. Carlsmed is also trading at a lower price-to-earnings ratio, making it the more affordable of the two stocks currently.
- The analysis is based on data as of March 27, 2026.
The players
Carlsmed
A small-cap manufacturing company focused on developing AI-enabled personalized spine surgery solutions.
Predictive Oncology
A small-cap manufacturing company focused on developing personalized cancer therapies using artificial intelligence, operating in four segments: Helomics, zPREDICTA, Soluble, and Skyline.
The takeaway
Based on the analysis, Carlsmed appears to be the superior business compared to Predictive Oncology, with stronger consensus ratings from analysts, better financial metrics, and a more affordable valuation. However, both companies are operating in the competitive healthcare technology space, so investors should continue to monitor their respective performances and developments.
